Nachrichten zur Vaxcyte Inc. Aktie

Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes

SAN CARLOS, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company,…

Vaxcyte, Inc. (PCVX) Discusses Top Line Results From OPUS-1 Phase 3 Trial of VAX-31 Pneumococcal Vaccine Candidate Transcript

…

Vaxcyte: Phase-3-Erfolg für VAX-31: Schutz vor 31 Bakterienstämmen lässt Aktie um 50% steigen

Vaxcyte zielt mit Proteinkonjugaten auf Präventionsmärkte ab. OPUS-1-Daten belegen die Wirksamkeit von VAX-31 bei Erwachsenen. Der Konzern bereitet Zulassungen…

Vaxcyte, Inc. (PCVX) Q4 2025 Earnings Call Transcript

…

Vaxcyte Inc.: Needham sieht 143 % Kurspotenzial und nennt den Titel eine Top-Empfehlung

Pionierarbeit durch zellfreie Impfstoffsynthese Vaxcyte Inc. (PCVX) versteht sich als treibende Kraft in der Modernisierung der Impfstoffentwicklung und nutzt eine…

Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study

SAN CARLOS, Calif., March 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company…

Vaxcyte, Inc. (PCVX) Q4 2024 Earnings Call Transcript

…

Alexandria Announces Long-Term Lease at San Carlos Mega Campus

ARE announces that it has executed a 10-year lease with Vaxcyte, Inc., a clinical-stage biopharmaceutical company.…

Vaxcyte Announces Pricing of $1.3 Billion Public Offering

SAN CARLOS, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company…

Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

SAN CARLOS, Calif., Sept. 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company…

Vaxcyte, Inc. (PCVX) Q4 2023 Earnings Call Transcript

…

Vaxcyte, Inc. (PCVX) Is Up 2.14% in One Week: What You Should Know

Does Vaxcyte, Inc. (PCVX) have what it takes to be a top stock pick for momentum investors? Lets find out.…

dpa-AFX ProFeed